NHS England Awarded Framework Agreement for Proprietary Pharmaceuticals Supply in Midlands and East (Tranche A)

About

NHS England awarded a framework agreement to multiple suppliers, including AbbVie Ltd, Actavis UK Limited, Allergan Limited, Amgen Limited, Bristol-Myers Squibb Pharmaceuticals Limited, Chugai Pharma U.K.

Ltd., Eli Lilly and Company Limited, Ferring Pharmaceuticals Limited, and Gilead Sciences, for the supply of proprietary pharmaceuticals to participating authorities in the NHS Midlands and East region.

The framework period is from 1 March 2018 to 29 February 2020, with an option to extend for up to 24 months at the Authority's discretion.

The framework is intended for use by the Department of Health, Public Health England, and the NHS in England, and may also be used by private sector contractors and agents working on their behalf.

The advertised awarding value is £163 million over the full potential four-year period, with the initial two-year period carrying a value of £81.5 million (£40.75 million per annum).